|
1
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020:
GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Lohitesh K, Chowdhury R and Mukherjee S:
Resistance a major hindrance to chemotherapy in hepatocellular
carcinoma: An insight. Cancer Cell Int. 18:442018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Phi LTH, Sari IN, Yang YG, Lee SH, Jun N,
Kim KS, Lee YK and Kwon HY: Cancer stem cells (CSCs) in drug
resistance and their therapeutic implications in cancer treatment.
Stem Cells Int. 2018:54169232018. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Chang JC: Cancer stem cells: Role in tumor
growth, recurrence, metastasis, and treatment resistance. Medicine
(Baltimore). 95 (1 Suppl 1):S20–S25. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Adhikari AS, Agarwal N and Iwakuma T:
Metastatic potential of tumor-initiating cells in solid tumors.
Front Biosci (Landmark Ed). 16:1927–1938. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lee TK, Cheung VC and Ng IO: Liver
tumor-initiating cells as a therapeutic target for hepatocellular
carcinoma. Cancer Lett. 338:101–109. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kim HM, Haraguchi N, Ishii H, Ohkuma M,
Okano M, Mimori K, Eguchi H, Yamamoto H, Nagano H, Sekimoto M, et
al: Increased CD13 expression reduces reactive oxygen species,
promoting survival of liver cancer stem cells via an
epithelial-mesenchymal transition-like phenomenon. Ann Surg Oncol.
19 (Suppl 3):S539–S548. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Subramanian S and Steer CJ: Special issue:
MicroRNA regulation in health and disease. Genes (Basel).
10:4572019. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Vasudevan S: Posttranscriptional
upregulation by microRNAs. Wiley Interdiscip Rev RNA. 3:311–330.
2012. View
Article : Google Scholar : PubMed/NCBI
|
|
10
|
Giovannini C, Minguzzi M, Baglioni M,
Fornari F, Giannone F, Ravaioli M, Cescon M, Chieco P, Bolondi L
and Gramantieri L: Suppression of p53 by Notch3 is mediated by
cyclin G1 and sustained by MDM2 and miR-221 axis in hepatocellular
carcinoma. Oncotarget. 5:10607–10620. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Sun C, Yao X, Jiang Q and Sun X: miR-106b
targets DAB2 to promote hepatocellular carcinoma cell proliferation
and metastasis. Oncol Lett. 16:3063–3069. 2018.PubMed/NCBI
|
|
12
|
Meng F, Henson R, Wehbe-Janek H, Ghoshal
K, Jacob ST and Patel T: MicroRNA-21 regulates expression of the
PTEN tumor suppressor gene in human hepatocellular cancer.
Gastroenterology. 133:647–658. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Simerzin A, Zorde-Khvalevsky E, Rivkin M,
Adar R, Zucman-Rossi J, Couchy G, Roskams T, Govaere O, Oren M,
Giladi H and Galun E: The liver-specific microRNA-122*, the
complementary strand of microRNA-122, acts as a tumor suppressor by
modulating the p53/mouse double minute 2 homolog circuitry.
Hepatology. 64:1623–1636. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Girard M, Jacquemin E, Munnich A, Lyonnet
S and Henrion-Caude A: miR-122, a paradigm for the role of
microRNAs in the liver. J Hepatol. 48:648–656. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Cheung O, Puri P, Eicken C, Contos MJ,
Mirshahi F, Maher JW, Kellum JM, Min H, Luketic VA and Sanyal AJ:
Nonalcoholic steatohepatitis is associated with altered hepatic
MicroRNA expression. Hepatology. 48:1810–1820. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Hsu SH, Wang B, Kota J, Yu J, Costinean S,
Kutay H, Yu L, Bai S, La Perle K, Chivukula RR, et al: Essential
metabolic, anti-inflammatory, and anti-tumorigenic functions of
miR-122 in liver. J Clin Invest. 122:2871–2883. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Tsai WC, Hsu SD, Hsu CS, Lai TC, Chen SJ,
Shen R, Huang Y, Chen HC, Lee CH, Tsai TF, et al: MicroRNA-122
plays a critical role in liver homeostasis and
hepatocarcinogenesis. J Clin Invest. 122:2884–2897. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Xu Y, Bu X, Dai C and Shang C: High serum
microRNA-122 level is independently associated with higher overall
survival rate in hepatocellular carcinoma patients. Tumour Biol.
36:4773–4776. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kim SS, Nam JS, Cho HJ, Won JH, Kim JW, Ji
JH, Yang MJ, Park JH, Noh CK, Shin SJ, et al: Plasma micoRNA-122 as
a predictive marker for treatment response following transarterial
chemoembolization in patients with hepatocellular carcinoma. J
Gastroenterol Hepatol. 32:199–207. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Celen AB and Sahin U: Sumoylation on its
25th anniversary: Mechanisms, pathology, and emerging concepts.
FEBS J. 287:3110–3140. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zubiete-Franco I, García-Rodríguez JL,
Lopitz-Otsoa F, Serrano-Macia M, Simon J, Fernández-Tussy P,
Barbier-Torres L, Fernández-Ramos D, Gutiérrez-de-Juan V, López de
Davalillo S, et al: SUMOylation regulates LKB1 localization and its
oncogenic activity in liver cancer. EBioMedicine. 40:406–421. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Qin Y, Bao H, Pan Y, Yin M, Liu Y, Wu S
and Li H: SUMOylation alterations are associated with multidrug
resistance in hepatocellular carcinoma. Mol Med Rep. 9:877–881.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Li JH, Liu S, Zhou H, Qu LH and Yang JH:
starBase v2.0: Decoding miRNA-ceRNA, miRNA-ncRNA and protein-RNA
interaction networks from large-scale CLIP-Seq data. Nucleic Acids
Res. 42:(Database Issue). D92–D97. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Hu Y and Smyth GK: ELDA: Extreme limiting
dilution analysis for comparing depleted and enriched populations
in stem cell and other assays. J Immunol Methods. 347:70–78. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Tomasi ML and Ramani K: SUMOylation and
phosphorylation cross-talk in hepatocellular carcinoma. Transl
Gastroenterol Hepatol. 3:202018. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Yuan H, Lu Y, Chan YT, Zhang C, Wang N and
Feng Y: The role of protein SUMOylation in human hepatocellular
carcinoma: A potential target of new drug discovery and
development. Cancers (Basel). 13:57002021. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Mohammed MK, Shao C, Wang J, Wei Q, Wang
X, Collier Z, Tang S, Liu H, Zhang F, Huang J, et al: Wnt/β-catenin
signaling plays an ever-expanding role in stem cell self-renewal,
tumorigenesis and cancer chemoresistance. Genes Dis. 3:11–40. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Cao W, Chen HD, Yu YW, Li N and Chen WQ:
Changing profiles of cancer burden worldwide and in China: A
secondary analysis of the global cancer statistics 2020. Chin Med J
(Engl). 134:783–791. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Chen Z, Xie H, Hu M, Huang T, Hu Y, Sang N
and Zhao Y: Recent progress in treatment of hepatocellular
carcinoma. Am J Cancer Res. 10:2993–3036. 2020.PubMed/NCBI
|
|
31
|
Gramantieri L, Fornari F, Callegari E,
Sabbioni S, Lanza G, Croce CM, Bolondi L and Negrini M: MicroRNA
involvement in hepatocellular carcinoma. J Cell Mol Med.
12:2189–2204. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Geiss-Friedlander R and Melchior F:
Concepts in sumoylation: A decade on. Nat Rev Mol Cell Biol.
8:947–956. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Yeh ETH: SUMOylation and De-SUMOylation:
Wrestling with life's processes. J Biol Chem. 284:8223–8227. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Liu Q, Zhou B, Liao R, Zhou X and Yan X:
PIAS4, upregulated in hepatocellular carcinoma, promotes
tumorigenicity and metastasis. J Cell Biochem. 121:3372–3381. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Ong JR, Bamodu OA, Khang NV, Lin YK, Yeh
CT, Lee WH and Cherng YG: SUMO-activating enzyme subunit 1 (SAE1)
is a promising diagnostic cancer metabolism biomarker of
hepatocellular carcinoma. Cells. 10:1782021. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Tsui YM, Chan LK and Ng IO: Cancer
stemness in hepatocellular carcinoma: Mechanisms and translational
potential. Br J Cancer. 122:1428–1440. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Cui CP, Wong CC, Kai AK, Ho DW, Lau EY,
Tsui YM, Chan LK, Cheung TT, Chok KS, Chan ACY, et al: SENP1
promotes hypoxia-induced cancer stemness by HIF-1α deSUMOylation
and SENP1/HIF-1α positive feedback loop. Gut. 66:2149–2159. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Wang N, Wang Q, Shen D, Sun X, Cao X and
Wu D: Downregulation of microRNA-122 promotes proliferation,
migration, and invasion of human hepatocellular carcinoma cells by
activating epithelial-mesenchymal transition. Onco Targets Ther.
9:2035–2047. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Turato C, Fornari F, Pollutri D, Fassan M,
Quarta S, Villano G, Ruvoletto M, Bolondi L, Gramantieri L and
Pontisso P: MiR-122 targets SerpinB3 and is involved in sorafenib
resistance in hepatocellular carcinoma. J Clin Med. 8:1712019.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Fornari F, Gramantieri L, Giovannini C,
Veronese A, Ferracin M, Sabbioni S, Calin GA, Grazi GL, Croce CM,
Tavolari S, et al: MiR-122/cyclin G1 interaction modulates p53
activity and affects doxorubicin sensitivity of human
hepatocarcinoma cells. Cancer Res. 69:5761–5767. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Vilchez V, Turcios L, Marti F and Gedaly
R: Targeting Wnt/β-catenin pathway in hepatocellular carcinoma
treatment. World J Gastroenterol. 22:823–832. 2016. View Article : Google Scholar : PubMed/NCBI
|
